Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has type 2 diabetes mellitus~* Males~* Females who are highly unlikely to become pregnant~* Participants poorly controlled without taking any, or taking one or two oral antidiabetic medications~Exclusion Criteria:~* Participant has a history of type 1 diabetes mellitus or history of ketoacidosis~* Participant required insulin therapy within the prior 8 weeks~* Participant is on or has been taking TZDs such as Actos® (pioglitazone) or Avandia® (rosiglitazone) within the prior 12 weeks of the screening visit

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- sitagliptin (Type: EXPERIMENTAL): Participants randomized to this arm will be administered sitagliptin 100mg daily, for six weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this arm will be administered matching placebo, daily for six weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).